COMP <GO>
NTLA vs LNTH // PIOTROSKI F-SCORE QUALITY
Intellia Therapeutics Inc. (NASDAQ) VS. Lantheus Holdings Inc. (NASDAQ) • 15-METRIC TALLY: NTLA 1
— LNTH 8
▲ PIOTROSKI F-SCORE QUALITY LEADER: LNTH
LAST: $11.66 (-6.50%) • MKT CAP: $1.75B
piotroski-score
4/9
LAST: $100.31 (-0.15%) • MKT CAP: $6.56B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NTLA VS. LNTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NTLA | LNTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 61.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.30% | -55.30 | LNTH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -21.35% | 4.90% | -26.25 | LNTH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 20.20% | -80.20 | LNTH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 15.20% | -75.20 | LNTH | /net-margins <GO> |
| Revenue Growth (YoY) | 16.90% | 0.50% | +16.40 | NTLA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.17 | 5.34 | -4.17 | LNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 7/9 | -3.00 | LNTH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 55.8 | -3.60 | LNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.88 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.75B | $6.56B | -$4.81B | LNTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NTLA REV | LNTH REV | NTLA GROSS % | LNTH GROSS % | NTLA FCF | LNTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $67.7M | $1.54B | — | 61.1% | -$395.9M | $320.8M |
| FY 2024 | $57.9M | $1.53B | — | 64.4% | -$354.7M | $475.7M |
| FY 2023 | $36.3M | $1.30B | — | — | -$394.1M | $246.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NTLA // BETA —
LNTH // BETA 0.88